101 related articles for article (PubMed ID: 22564423)
1. Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma.
Kast RE; Halatsch ME
Arch Med Res; 2012 Apr; 43(3):243-7. PubMed ID: 22564423
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models.
Williams RN; Parsons SL; Morris TM; Rowlands BJ; Watson SA
Eur J Surg Oncol; 2005 Nov; 31(9):1042-50. PubMed ID: 15993560
[TBL] [Abstract][Full Text] [Related]
3. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Kast RE; Karpel-Massler G; Halatsch ME
Oncotarget; 2014 Sep; 5(18):8052-82. PubMed ID: 25211298
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase-9/tissue inhibitors of metalloproteinase-1 expression and atrial structural remodeling in a dog model of atrial fibrillation: inhibition with angiotensin-converting enzyme.
Zhang W; Zhong M; Yang GR; Li JP; Guo C; Wang Z; Zhang Y
Cardiovasc Pathol; 2008; 17(6):399-409. PubMed ID: 18706834
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory profiles of captopril on matrix metalloproteinase-9 activity.
Yamamoto D; Takai S; Miyazaki M
Eur J Pharmacol; 2008 Jul; 588(2-3):277-9. PubMed ID: 18501888
[TBL] [Abstract][Full Text] [Related]
6. Effect of angiotensin-converting enzyme inhibitor on matrix metalloproteinase-9 activity in patients with Kawasaki disease.
Inoue N; Takai S; Jin D; Okumura K; Okamura N; Kajiura M; Yoshikawa S; Kawamura N; Tamai H; Miyazaki M
Clin Chim Acta; 2010 Feb; 411(3-4):267-9. PubMed ID: 19945447
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinase-2 inhibition by temocapril and its important role in peritoneal transport.
Yamamoto D; Takai S; Akimoto T; Hirahara I; Ito C; Muto S; Kusano E
Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):864-8. PubMed ID: 23013132
[TBL] [Abstract][Full Text] [Related]
8. Captopril inhibits Matrix Metalloproteinase-2 and extends survival as a temozolomide adjuvant in an intracranial gliosarcoma model.
Pinheiro L; Perdomo-Pantoja A; Casaos J; Huq S; Paldor I; Vigilar V; Mangraviti A; Wang Y; Witham TF; Brem H; Tyler B
Clin Neurol Neurosurg; 2021 Aug; 207():106771. PubMed ID: 34198223
[TBL] [Abstract][Full Text] [Related]
9. Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy.
Yamamoto D; Takai S; Hirahara I; Kusano E
Clin Chim Acta; 2010 May; 411(9-10):762-4. PubMed ID: 20184869
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
11. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Kast RE; Boockvar JA; Brüning A; Cappello F; Chang WW; Cvek B; Dou QP; Duenas-Gonzalez A; Efferth T; Focosi D; Ghaffari SH; Karpel-Massler G; Ketola K; Khoshnevisan A; Keizman D; Magné N; Marosi C; McDonald K; Muñoz M; Paranjpe A; Pourgholami MH; Sardi I; Sella A; Srivenugopal KS; Tuccori M; Wang W; Wirtz CR; Halatsch ME
Oncotarget; 2013 Apr; 4(4):502-30. PubMed ID: 23594434
[TBL] [Abstract][Full Text] [Related]
12. ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats.
Liebetrau M; Burggraf D; Wunderlich N; Jäger G; Linz W; Hamann GF
Neurosci Lett; 2005 Mar; 376(3):205-9. PubMed ID: 15721222
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme inhibitors in hypertension: a review.
Salvetti A; Pedrinelli R; Arzilli F; Abdel-Haq B; Magagna A; Lucarini A; Graziadei L; Nuccorini A; Taddei S
Int J Clin Pharmacol Res; 1985; 5(6):429-38. PubMed ID: 3005182
[TBL] [Abstract][Full Text] [Related]
14. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP.
Reinhardt D; Sigusch HH; Hensse J; Tyagi SC; Körfer R; Figulla HR
Heart; 2002 Nov; 88(5):525-30. PubMed ID: 12381651
[TBL] [Abstract][Full Text] [Related]
15. Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension.
Bolbrinker J; Markovic S; Wehland M; Melenhorst WB; van Goor H; Kreutz R
J Pharmacol Exp Ther; 2006 Jan; 316(1):8-16. PubMed ID: 16166267
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of matrix metalloproteinase-9 activity by lisinopril after myocardial infarction in hamsters.
Takai S; Yamamoto D; Jin D; Inagaki S; Yoshikawa K; Tanaka K; Miyazaki M
Eur J Pharmacol; 2007 Jul; 568(1-3):231-3. PubMed ID: 17512521
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram.
Shian SG; Kao YR; Wu FY; Wu CW
Mol Pharmacol; 2003 Nov; 64(5):1076-84. PubMed ID: 14573756
[TBL] [Abstract][Full Text] [Related]
18. Comparison of angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockade for the prevention of premalignant changes in the liver.
Mansour MA; Al-Ismaeel H; Al-Rikabi AC; Al-Shabanah OA
Life Sci; 2011 Aug; 89(5-6):188-94. PubMed ID: 21699905
[TBL] [Abstract][Full Text] [Related]
19. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
[TBL] [Abstract][Full Text] [Related]
20. Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
Bralet J; Marie C; Mossiat C; Lecomte JM; Gros C; Schwartz JC
J Pharmacol Exp Ther; 1994 Jul; 270(1):8-14. PubMed ID: 8035346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
